SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liposarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms SU2C-SARC032
- 05 Jun 2018 Study design was presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 16 Mar 2018 Status changed from active, no longer recruiting to recruiting.
- 26 Jan 2018 Status changed from recruiting to active, no longer recruiting.